质粒
转导(生物物理学)
离体
分子生物学
效价
质体制备
病毒载体
生物
转染
DNA
遗传增强
体内
病毒学
细胞培养
重组DNA
基因
遗传学
病毒
生物化学
PBR322电话
作者
Lakshmi Sastry,Yi Xu,Ryan Cooper,Karen E. Pollok,Kenneth Cornetta
出处
期刊:Human Gene Therapy
[Mary Ann Liebert, Inc.]
日期:2004-02-01
卷期号:15 (2): 221-226
被引量:74
标识
DOI:10.1089/104303404772680029
摘要
To improve the purity of lentiviral vector supernatants for clinical studies we have evaluated plasmid DNA removal from lentiviral vectors and also the extent of plasmid DNA associated with transduced CD34 cells in an ex vivo transduction protocol. Optimal conditions of plasmid DNA removal by benzonase treatment were established by varying the temperature, time, and benzonase concentrations in the reaction mix and were determined to be 50 units of benzonase per milliliter of vector supernatant at 37 degrees C, for 15 min. No plasmid DNA was detected, suggesting efficient plasmid degradation was achieved under these experimental conditions. The infectious titer of benzonase-treated lentiviral vector (RRL-CMV-GFP) was nearly identical to the titer of untreated vector (2.3 +/- 0.3 x 10(6) transduction units per milliliter (TU/ml) and 2.7 +/- 0.3 x 10(6) TU/ml, respectively). Analysis of plasmid DNA in concentrated lentiviral vectors shows that concentration substantially decreases the amount of DNA per TU. Analysis of the extent of plasmid DNA associated with transduced CD34 cells in an ex vivo transduction protocol suggests that a minimal amount of plasmid is transferred to transduced cells if the vector supernatant was not previously treated with benzonase. In conclusion, benzonase treatment is effective in eliminating plasmid DNA from vector supernatants and treatment does not affect infectious titers. However, because there is minimal transfer of plasmid DNA to transduced cells under ex vivo transduction conditions, DNA removal from lentiviral vectors may not be essential for all ex vivo clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI